450 related articles for article (PubMed ID: 34145969)
1. Indoleamine 2,3-dioxygenase 1 (IDO1): an up-to-date overview of an eclectic immunoregulatory enzyme.
Pallotta MT; Rossini S; Suvieri C; Coletti A; Orabona C; Macchiarulo A; Volpi C; Grohmann U
FEBS J; 2022 Oct; 289(20):6099-6118. PubMed ID: 34145969
[TBL] [Abstract][Full Text] [Related]
2. Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor.
Song X; Si Q; Qi R; Liu W; Li M; Guo M; Wei L; Yao Z
Front Immunol; 2021; 12():800630. PubMed ID: 35003126
[TBL] [Abstract][Full Text] [Related]
3. The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment.
Gostner JM; Becker K; Überall F; Fuchs D
Expert Opin Ther Targets; 2015 May; 19(5):605-15. PubMed ID: 25684107
[TBL] [Abstract][Full Text] [Related]
4. Tryptophan 2,3-Dioxygenase Expression Identified in Murine Decidual Stromal Cells Is Not Essential for Feto-Maternal Tolerance.
Hoffmann D; Dvorakova T; Schramme F; Stroobant V; Van den Eynde BJ
Front Immunol; 2020; 11():601759. PubMed ID: 33363543
[TBL] [Abstract][Full Text] [Related]
5. Role of indoleamine 2,3-dioxygenase in health and disease.
Yeung AW; Terentis AC; King NJ; Thomas SR
Clin Sci (Lond); 2015 Oct; 129(7):601-72. PubMed ID: 26186743
[TBL] [Abstract][Full Text] [Related]
6. Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation.
Mondanelli G; Coletti A; Greco FA; Pallotta MT; Orabona C; Iacono A; Belladonna ML; Albini E; Panfili E; Fallarino F; Gargaro M; Manni G; Matino D; Carvalho A; Cunha C; Maciel P; Di Filippo M; Gaetani L; Bianchi R; Vacca C; Iamandii IM; Proietti E; Boscia F; Annunziato L; Peppelenbosch M; Puccetti P; Calabresi P; Macchiarulo A; Santambrogio L; Volpi C; Grohmann U
Proc Natl Acad Sci U S A; 2020 Feb; 117(7):3848-3857. PubMed ID: 32024760
[TBL] [Abstract][Full Text] [Related]
7. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
Kim M; Tomek P
Front Immunol; 2021; 12():636081. PubMed ID: 33708223
[TBL] [Abstract][Full Text] [Related]
8. Pathogenetic Interplay Between IL-6 and Tryptophan Metabolism in an Experimental Model of Obesity.
Mondanelli G; Albini E; Orecchini E; Pallotta MT; Belladonna ML; Ricci G; Grohmann U; Orabona C
Front Immunol; 2021; 12():713989. PubMed ID: 34394118
[TBL] [Abstract][Full Text] [Related]
9. Indoleamine 2,3-dioxygenase 1 activation in mature cDC1 promotes tolerogenic education of inflammatory cDC2 via metabolic communication.
Gargaro M; Scalisi G; Manni G; Briseño CG; Bagadia P; Durai V; Theisen DJ; Kim S; Castelli M; Xu CA; Meyer Zu Hörste G; Servillo G; Della Fazia MA; Mencarelli G; Ricciuti D; Padiglioni E; Giacchè N; Colliva C; Pellicciari R; Calvitti M; Zelante T; Fuchs D; Orabona C; Boon L; Bessede A; Colonna M; Puccetti P; Murphy TL; Murphy KM; Fallarino F
Immunity; 2022 Jun; 55(6):1032-1050.e14. PubMed ID: 35704993
[TBL] [Abstract][Full Text] [Related]
10. Interferon-γ induces a tryptophan-selective amino acid transporter in human colonic epithelial cells and mouse dendritic cells.
Bhutia YD; Babu E; Ganapathy V
Biochim Biophys Acta; 2015 Feb; 1848(2):453-62. PubMed ID: 25450809
[TBL] [Abstract][Full Text] [Related]
11. Forced IDO1 expression in dendritic cells restores immunoregulatory signalling in autoimmune diabetes.
Pallotta MT; Orabona C; Bianchi R; Vacca C; Fallarino F; Belladonna ML; Volpi C; Mondanelli G; Gargaro M; Allegrucci M; Talesa VN; Puccetti P; Grohmann U
J Cell Mol Med; 2014 Oct; 18(10):2082-91. PubMed ID: 25215657
[TBL] [Abstract][Full Text] [Related]
12. Investigation of the kynurenine pathway in Indoleamine 2, 3 dioxygenase deficient mice with inflammatory arthritis.
Kolodziej L
Transgenic Res; 2013 Oct; 22(5):1049-54. PubMed ID: 23417792
[TBL] [Abstract][Full Text] [Related]
13. Tryptophan depletion sensitizes the AHR pathway by increasing AHR expression and GCN2/LAT1-mediated kynurenine uptake, and potentiates induction of regulatory T lymphocytes.
Solvay M; Holfelder P; Klaessens S; Pilotte L; Stroobant V; Lamy J; Naulaerts S; Spillier Q; Frédérick R; De Plaen E; Sers C; Opitz CA; Van den Eynde BJ; Zhu J
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344101
[TBL] [Abstract][Full Text] [Related]
14. Tryptophan metabolism activation by indoleamine 2,3-dioxygenase in adipose tissue of obese women: an attempt to maintain immune homeostasis and vascular tone.
Wolowczuk I; Hennart B; Leloire A; Bessede A; Soichot M; Taront S; Caiazzo R; Raverdy V; Pigeyre M; ; Guillemin GJ; Allorge D; Pattou F; Froguel P; Poulain-Godefroy O
Am J Physiol Regul Integr Comp Physiol; 2012 Jul; 303(2):R135-43. PubMed ID: 22592557
[TBL] [Abstract][Full Text] [Related]
15. Indoleamine 2,3-dioxygenase 1 in circumventing checkpoint inhibitor responses: Updated.
Charehjoo A; Majidpoor J; Mortezaee K
Int Immunopharmacol; 2023 May; 118():110032. PubMed ID: 36933494
[TBL] [Abstract][Full Text] [Related]
16. Distinct roles of immunoreceptor tyrosine-based motifs in immunosuppressive indoleamine 2,3-dioxygenase 1.
Albini E; Rosini V; Gargaro M; Mondanelli G; Belladonna ML; Pallotta MT; Volpi C; Fallarino F; Macchiarulo A; Antognelli C; Bianchi R; Vacca C; Puccetti P; Grohmann U; Orabona C
J Cell Mol Med; 2017 Jan; 21(1):165-176. PubMed ID: 27696702
[TBL] [Abstract][Full Text] [Related]
17. A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression.
Klar R; Michel S; Schell M; Hinterwimmer L; Zippelius A; Jaschinski F
Cancer Immunol Immunother; 2020 Jan; 69(1):57-67. PubMed ID: 31802183
[TBL] [Abstract][Full Text] [Related]
18. Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives.
Peyraud F; Guegan JP; Bodet D; Cousin S; Bessede A; Italiano A
Front Immunol; 2022; 13():807271. PubMed ID: 35173722
[TBL] [Abstract][Full Text] [Related]
19. Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0.
Grobben Y; de Man J; van Doornmalen AM; Muller M; Willemsen-Seegers N; Vu-Pham D; Mulder WR; Prinsen MBW; de Wit J; Sterrenburg JG; van Cauter F; den Ouden JE; van Altena AM; Massuger LF; Uitdehaag JCM; Buijsman RC; Zaman GJR
Front Immunol; 2020; 11():609490. PubMed ID: 33584686
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients.
Zhou QH; Han H; Lu JB; Liu TY; Huang KB; Deng CZ; Li ZS; Chen JP; Yao K; Qin ZK; Liu ZW; Li YH; Guo SJ; Ye YL; Zhou FJ; Liu RY
Cancer Commun (Lond); 2020 Jan; 40(1):3-15. PubMed ID: 32125093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
